Actively Recruiting
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Led by Ruijin Hospital · Updated on 2024-07-03
356
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group). The 3-year overall survival rate is the primary outcome.
CONDITIONS
Official Title
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed cT2-T4a, N0-N+, M0 resectable esophageal squamous cell carcinoma
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patients approve and sign the informed consent
You will not qualify if you...
- Active autoimmune disease or history of autoimmune disease
- Condition requiring systemic treatment with corticosteroids or other immunosuppressive medications
- History of symptomatic interstitial lung disease
- Allergy to study drug components
- Women who are pregnant or breast-feeding
- Men with female partners of childbearing potential not willing to use contraception
- Prior chemotherapy, radiotherapy, targeted therapy, or immune therapy for this or any other malignancy
- Medical conditions that may make study drug administration hazardous or obscure toxicity or adverse event interpretation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin hospital
Shanghai, China
Actively Recruiting
Research Team
H
Hecheng Li
CONTACT
C
Chengqiang Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here